FlandersBio on Twitter

Follow us on Twitter

Archive for July 2011 - News

Archive for July 2011 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

6-jarig meisje met 'cerebrale spasticiteit' wordt met eigen stamcellen uit navelstrengbloed behandeld

28.07.2011

6 jaar geleden beslisten Portugese ouders bij de geboorte van hun dochtertje, het navelstrengbloed op te laten slaan bij Cryo-Save (Euronext: CRYO, “Cryo-Save”). Deze week is het zieke meisje in de VS behandeld met haar eigen stamcellen. Een medisch hoogstandje, maar niet de enige, want steeds meer aandoeningen worden in klinische testen met autologe (eigen) stamcellen aangepakt. read more

Initial observations of Ablynx's Phase II TTP Programme presented at ISTH congress

28.07.2011

Ablynx [Euronext Brussels: ABLX] today announced that initial observations of the on-going Phase II study with the anti-von Willebrand factor (vWF) Nanobody ALX-0081/ALX-0681 in patients with thrombotic thrombocytopenic purpura (TTP) were presented at the 13th Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Kyoto, Japan. read more

Common drugs initiate a molecular pas de quatre at the surface of the cell membrane

26.07.2011

In an article in Nature, scientists from Stanford University, University of Wisconsin and VIB-Vrije Universiteit Brussel now reveal the complete three-dimensional atomic structure of an activated GPCR — the beta-2 adrenergic receptor (beta-2AR) — in a complex with its G protein. This is an important step towards the understanding of how the receptors actually work. Beta-2 AR is activated by the hormones adrenaline and noradrenaline. Activation of the receptor lies at the basis of the body's fight-or-flight response by speeding up the heart, increasing blood pressure and opening airways. As a result, it is a key target for anti-asthma and blood pressure medications. read more

argen-x announces non-exclusive license with biowa FOR potelligent® technology

26.07.2011

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT® Technology. read more

Balance of the immune system determined by newly discovered T cells

26.07.2011

A newly discovered cell type helps to determine the balance of the immune system. The cells are derived from FoxP3(+) regulatory T cells, which recently have been demonstrated to suppress disease during transplantation. Nature Medicine and Blood, two high-ranking scientific journals, are publishing findings by the team of Adrian Liston from VIB and K.U.Leuven about this discovery. read more

Ablynx is granted GLP certificate for new GLP unit

26.07.2011

Ablynx [Euronext Brussels: ABLX] today announced that it has been granted a Certificate of Good Laboratory Practise (GLP) from the Belgian Scientific Institute of Public Health (IPH) for its new GLP unit at its headquarters in Ghent, Belgium, after having been inspected in May 2011. read more

Galapagos initiates Proof-of-Mechanism clinical study for candidate cachexia drug GLPG0492

20.07.2011

Galapagos NV (Euronext: GLPG) announced today that it has started a Phase I Proof-of-Mechanism study for GLPG0492, a candidate drug for cachexia (loss of weight and muscle mass) and potentially other indications, such as Duchenne muscular dystrophy. read more

De BD AutoShield™-veiligheidspennaald beperkt het risico op prikaccidenten voor gezondheidswerkers en verzorgers

19.07.2011

Erembodegem, België (19 juli 2011) – BD (Becton, Dickinson and Company), een toonaangevend internationaal bedrijf in medische technologie, brengt vandaag de 5mm BD AutoShield™-veiligheidspennaald op de markt. Het ontwerp van deze pennaalden is zodanig op veiligheid gericht dat gezondheidswerkers en medisch professionelen er diabetici veilig en comfortabel mee kunnen injecteren. read more

UGent en VUB richten gezamenlijk zaaikapitaalfonds op

18.07.2011

De Universiteit Gent en de Vrije Universiteit Brussel richten een nieuw interuniversitair zaaikapitaalfonds op. Doel van dit eerste interuniversitaire fonds is de technologie spin-off bedrijven van drie universitaire associaties - Associatie UGent, Universitaire Associatie Brussel en de Associatie Universiteit & Hogescholen Antwerpen - te financieren. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print